Celldex Therapeutics Inc.

NASDAQ: CLDX · Real-Time Price · USD
25.00
0.06 (0.24%)
At close: Aug 15, 2025, 12:41 PM

Celldex Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
730K 695K 1.18M 3.19M 2.5M 156K 4.13M 1.52M 268K 967K 1.61M 407K 163K 174K 333K 153K 3.48M 685K
Cost of Revenue
n/a n/a 819K 786K 797K 775K 759K 767K 756K 726K 673K 21.57M 741K 17.06M 14.68M 13.56M 12.36M 12.72M
Gross Profit
730K 695K 356K 3.19M 1.7M -619K 3.37M 750K -488K 241K 940K -21.16M -578K -16.88M -14.35M -13.4M -8.88M -12.04M
Operating Income
-63.86M -62.74M -56.03M -52.13M -46.32M -40.61M -47.63M -41.24M -33.2M -32.47M -27.89M -27.7M -36.4M -23.26M -20.34M -20.82M -13.44M -16.64M
Interest Income
7.26M 8.94M 8.94M 10.01M 10.47M 7.8M 4.32M 2.98M 2.7M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-56.6M -53.8M -47.09M -42.12M -35.84M -32.81M -43.31M -38.26M -30.5M -29.36M -26.49M -26.78M -36M -23.05M -20.15M -20.68M -13.37M -16.54M
Net Income
-56.6M -53.8M -47.09M -42.12M -35.84M -32.81M -43.31M -38.26M -30.5M -22.41M -23.69M -26.78M -52.57M -21.56M -20.15M -20.45M -13.37M -16.54M
Selling & General & Admin
10.39M 10.82M 10.26M 10.05M 9.13M 9.1M 8.83M 8.22M 7.22M 6.64M 6.6M 6.53M 7.15M 6.91M 6.24M 5.82M 4.31M 4.12M
Research & Development
54.2M 52.61M 46.12M 3K 38.89M 30.89M 29.67M 34.53M 26.25M 26.8M 22.9M 21.57M 20.73M 17.06M 14.68M 13.56M 12.36M 12.72M
Other Expenses
n/a n/a n/a 45.26M n/a n/a n/a -767K 26.24M n/a n/a n/a 8.67M 16.49M n/a 1.6M 12.59M 13.2M
Operating Expenses
64.59M 63.43M 56.38M 55.32M 48.02M 39.99M 38.5M 41.99M 33.47M 33.44M 29.5M 28.1M 27.89M 23.97M 20.92M 19.38M 16.66M 16.84M
Interest Expense
n/a n/a n/a n/a n/a n/a 3.11M n/a n/a n/a n/a n/a n/a n/a n/a 2.91M n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
64.59M 63.43M 57.2M 55.32M 48.81M 40.76M 51.76M 42.76M 33.47M 33.44M 29.5M 28.1M 27.89M 23.97M 20.92M 19.38M 16.66M 16.84M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a -6.95M -2.8M n/a 16.56M -1.49M n/a -227K n/a n/a
Shares Outstanding (Basic)
66.39M 66.38M 66.35M 66.29M 66.02M 58.87M 52.03M 47.26M 47.25M 47.21M 47.13M 46.92M 46.76M 46.74M 46.58M 45.45M 39.33M 39.38M
Shares Outstanding (Diluted)
66.39M 66.38M 66.35M 66.29M 66.02M 58.87M 52.03M 47.26M 47.25M 47.21M 47.13M 46.92M 46.76M 46.74M 46.69M 45.45M 39.62M 39.61M
EPS (Basic)
-0.85 -0.81 -0.71 -0.64 -0.54 -0.56 -0.83 -0.81 -0.65 -0.47 -0.5 -0.57 -1.12 -0.46 -0.43 -0.45 -0.34 -0.42
EPS (Diluted)
-0.85 -0.81 -0.71 -0.64 -0.54 -0.56 -0.83 -0.81 -0.65 -0.47 -0.5 -0.57 -1.12 -0.46 -0.43 -0.45 -0.34 -0.42
EBITDA
-62.98M -61.87M -55.21M -51.34M -45.52M -39.83M -34.37M -40.47M -32.45M -31.75M -27.21M -27.02M -26.98M -22.98M -19.81M -18.47M -12.42M -15.38M
EBIT
-63.86M -62.74M -56.03M -52.13M -46.32M -40.61M -35.13M -41.24M -33.2M -32.47M -27.89M -27.7M -27.72M -23.79M -20.59M -19.23M -13.18M -16.16M
Depreciation & Amortization
873K 867K 819K 786K 797K 775K 759K 767K 756K 726K 673K 671K 741K 811K 777K 752K 764K 775K